U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07665788) titled 'Inhaled Amikacin Versus Placebo in Patients With Ventilator-associated Tracheobronchitis' on June 05.
Brief Summary: The primary objective of the AMIVAT trial is to assess whether a 5-day course of inhaled amikacin, compared to placebo, reduces the incidence of progression to ventilator-associated pneumonia (VAP) at day 28 in intensive care unit (ICU) patients with ventilator-associated tracheobronchitis (VAT). Transition from VAT to VAP will be defined as the occurrence of a first VAP episode due to the same pathogens than those responsible for VAT.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Ventilator-Asso...